UK Terminates COVID-19 Vaccine Deal, But Valneva Can Bounce Back
Two Other Vaccines Show Promise
The UK’s decision has hit Valneva’s share price hard, but its vaccine candidates in Chikungunya and Lyme’s disease should help the firm bounce back.
You may also be interested in...
Many of the many biotech companies that raised money to develop and repurpose their molecules to address the pandemic have started to unwind those efforts. What will this mean for the sector’s valuation?
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO
, and has underlined competitive threats to a key pipeline candidate.